Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920023 · ClinicalTrials.gov registry record · Phase 4
Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT00920023: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00920023 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920023, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection.
Interventions
- DRUG Superparamagnetic Iron Oxide Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920023
The ClinicalTrials.gov registry entry for NCT00920023 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Superparamagnetic Iron Oxide Magnetic Resonance Imaging is the first listed.
NCT00920023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00920023 about?
NCT00920023 is a clinical study titled "Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)". The purpose of this research study is to see if a specific kind of MRI, called Ultrasmall Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI), which uses an FDA-approved therapeutic agent(Feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastase...
What is the current status of trial NCT00920023?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2008-07. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00920023?
The interventions under investigation include: Superparamagnetic Iron Oxide Magnetic Resonance Imaging (DRUG).
Who is sponsoring clinical trial NCT00920023?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.